Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
The planned bioprocessing facility would support commercial manufacturing for biotech and pharmaceutical customers across Asia-Pacific.
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
The cleanroom operates under stringent ISO Class 5 conditions, using ultrapure water and air systems
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Subscribe To Our Newsletter & Stay Updated
